Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. (Q51155865)

31 March 2018

title

Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. (English)

1 reference

31 March 2018

main subject

Helicobacter pylori

0 references

antibiotic resistance

1 reference

2

Nayoung Kim

1 reference

31 March 2018

10

Hyun Chae Jung

1 reference

31 March 2018

Cheol Min Shin

7

object named as

Cheol Min Shin

1 reference

31 March 2018

Yoon Jin Choi

4

object named as

Yoon Jin Choi

1 reference

31 March 2018

author name string

Ju Yup Lee

1

1 reference

31 March 2018

Min Soo Kim

3

1 reference

31 March 2018

Jung Won Lee

5

1 reference

31 March 2018

Hyuk Yoon

6

1 reference

31 March 2018

Young Soo Park

8

1 reference

31 March 2018

Dong Ho Lee

9

1 reference

31 March 2018

publication date

6 March 2014

1 reference

31 March 2018

Digestive Diseases and Sciences

published in

1 reference

31 March 2018

volume

59

1 reference

31 March 2018

issue

6

1 reference

31 March 2018

page(s)

1235-1243

1 reference

31 March 2018

Clinical practice. Helicobacter pylori infection

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Genetics of response to proton pump inhibitor therapy: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Pharmacogenetics of the proton pump inhibitors: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Second‐line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Detailed comparison of basal and food-stimulated gastric acid secretion rates and serum gastrin concentrations in duodenal ulcer patients and normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Patterns of alcohol consumption and Helicobacter pylori infection: results of a population-based study from Germany among 6545 adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Efficacy of Helicobacter pylori eradication therapy in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Helicobacter pylori seroprevalence in patients with chronic obstructive pulmonary disease and its relation to pulmonary function tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Regional difference of antibiotic resistance of helicobacter pylori strains in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3093-7

Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients

21 January 2018

1 reference

12 December 2020

Helicobacter pylori infection and coronary heart disease in Japanese patients

1 reference

12 December 2020

Type 2 diabetes mellitus affects eradication rate ofHelicobacter pylori

1 reference

12 December 2020

Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection

1 reference

12 December 2020

A report card to grade Helicobacter pylori therapy

1 reference

12 December 2020

The trend of eradication rate of Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy

1 reference

12 December 2020

Age-dependent eradication of Helicobacter pylori with dual therapy

1 reference

12 December 2020

Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea

1 reference

12 December 2020

[The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years]

1 reference

12 December 2020

10.1007/S10620-014-3093-7

Identifiers

DOI

1 reference

31 March 2018

release_vs65thw4ybf2dg2rs2lywiklwm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vs65thw4ybf2dg2rs2lywiklwm

24 November 2022

mapped directly with Wikidata item

1 reference

31 March 2018